Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway
Filed with ASX · · 6 pages · English
Summary by 6ix AI
Dimerix Limited has secured a non-dilutive loan facility to enhance its cash runway for ongoing clinical trials and pipeline expansion. Dimerix is also negotiating for additional funding to further extend its cash runway beyond current trials. This funding arrangement is viewed as favorable compared to other proposals, allowing Dimerix to maintain control over capital drawdowns.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Dimerix
- DMX-200 Available To Patients Via Post-Trial Access Pathways
- Dimerix exclusively licenses DMX-200 in Greater China, South Korea and Southeast Asia to Everest Medicines
- Dimerix Licenses DMX200 to Everest for China and Asia Region
- Dimerix Quarterly Activities Report and Appendix 4C
- Blinded assessment of ACTION3 statistical assumptions complete
Later from Dimerix
- Dimerix Expands Pipeline with Acquisition of Phase 2 Asset
- Dimerix expands pipeline with acquisition of Phase 2 ready asset for acute kidney injury
- US Patent Granted for Dimerix New Asset DMX-652
- Dimerix Presents at Bioshares Summit 2026
- Dimerix Assumes Sponsorship of US IND for New Asset DMX-652
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix